Brigatinib
Brigatinib
{2-[(5-Chlor-2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}pyrimidin-4-yl)amino]phenyl}dimethyl-l5-phosphanon
Stoffgruppe
Antineoplastisches Mittel (ALK-Inhibitor)
Halbwertszeit
24 h